Skip to main content
. 2021 Oct 16;18:74. doi: 10.1186/s12981-021-00393-5

Table 2.

Drug class-specific resistance in participants on first and second-line ART regimens

ART regimen n NRTI resistance NNRTI resistance Major PI resistance
First-line 70 62 (88.6%) 65 (92.9%) 0
Second-line 44 36 (81.6%) 40 (90.9%) 6 (13.6%)

ART antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor